Kinase Inhibitors and Airway Inflammation.
From: Cell and Molecular Biology Group, Airways Disease Section, National Heart and Lung Institute, Imperial College London, Dovehouse Street, London, SW3, 6LY, United Kingdom. ian.adcock@imperial.ac.uk
European journal of pharmacology
- Publish Date: Mar 2006
- ISSN: 0014-2999
- Volume: 533
- Issue: 1-3
- Pages: 118-32
- Medium: Print
- Language: English
- Citation (JAMA): Adcock Ian M, Chung K Fan, Caramori Gaetano, et al. Kinase Inhibitors and Airway Inflammation.. Eur. J. Pharmacol. Mar 2006;533:118-32
Abstract
Kinases are believed to play a crucial role in the expression and activation of inflammatory mediators in the airway, in T-cell function and airway remodelling. Important kinases such as Inhibitor of kappaB kinase (IKK)2, mitogen activated protein (MAP) kinases and phsopho-inositol (PI)3 kinase regulate inflammation either through activation of pro-inflammatory transcription factors such as activating protein-1 (AP-1) and nuclear factor kappaB (NF-kappaB), which are activated in airway disease, or through regulation of mRNA half-life. Selective kinase inhibitors have been developed which reduce inflammation and some characteristics of disease in animal models. Targeting specific kinases that are overexpressed or over active in disease should allow for selective treatment of respiratory diseases. Interest in this area has intensified due to the success of the specific Abelson murine leukaemia viral oncogene (Abl) kinase inhibitor imatinib mesylate (Gleevec) in the treatment of chronic myelogenous leukaemia. Encouraging data from animal models and primary cells and early Phase I and II studies in other diseases suggest that inhibitors of p38 MAP kinase and IKK2 may prove to be useful novel therapies in the treatment of severe asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis and other inflammatory airway diseases.
Mesh Headings (Keywords): Animals, Anti-Inflammatory Agents, Asthma, Clinical Trials as Topic, Disease Models, Animal, Gene Expression Regulation, Humans, I-kappa B Kinase, MAP Kinase Signaling System, Mitogen-Activated Protein Kinases, Protein Kinase C, Protein Kinase Inhibitors, Pulmonary Disease, Chronic Obstructive
Check for Full Text / PubMed Unique Identifier (PMID): 16469308
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.